Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed and Refractory T-cell Lymphoma
NCT02309580Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2015
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in T-cell lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jan 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT02309580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309580.